Asset
Cyclophosphamide
Precision BioSciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04171843 | phase1 | terminated | 2020-04-30 | 2022-10-19 | Precision BioSciences, Inc. | A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma |
| NCT04030195 | phase1_2 | completed | 2020-03-24 | 2021-06-24 | Precision BioSciences, Inc. | Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL |
FDA applications (0)
This company has no applications containing this asset.